Tabula Rasa HealthCare (TRHC) 10-Q 10 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 31, 2016
Document and Entity Information
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Central Index Key	1,651,561
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		16,101,216
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash	$ 1,793	$ 2,026
Restricted cash		200
Accounts receivable, net	7,742	6,013
Inventories	2,609	2,304
Rebates receivable	305	1,064
Prepaid expenses and other current assets	636	522
Total current assets	13,085	12,129
Property and equipment, net	5,558	1,962
Software development costs, net	3,073	2,505
Goodwill	21,726	21,606
Intangible assets, net	26,229	17,687
Other assets	4,219	2,713
Total assets	73,890	58,602
Current liabilities:
Line of credit		10,000
Current portion of long term debt	29,193	13,526
Notes payable to related parties	250	250
Notes payable related to acquisition		15,620
Acquisition-related consideration payable	9,402	235
Acquisition-related contingent consideration	1,634	1,886
Accounts payable	5,998	6,808
Accrued expenses and other liabilities	3,584	3,244
Total current liabilities	50,061	51,569
Line of credit	16,000
Long term debt	1,119	430
Long-term acquisition-related contingent consideration	1,858	3,355
Warrant liability	4,930	5,569
Deferred income taxes	307	334
Other long-term liabilities	1,973
Total liabilities	76,248	61,257
Redeemable convertible preferred stock:
Total redeemable convertible preferred stock	26,534	28,973
Stockholder's deficit:
Common stock, $0.0001 par value; 27,836,869 shares authorized, 5,583,405 and 4,575,867 shares issued and outstanding at September 30, 2016 and December 31, 2015 respectively
Accumulated deficit	(28,892)	(31,628)
Total stockholder's deficit	(28,892)	(31,628)
Total liabilities, redeemable convertible preferred stock and stockholders' deficit	73,890	58,602
Series A and A-1 redeemable convertible preferred stock
Redeemable convertible preferred stock:
Total redeemable convertible preferred stock	6,859	6,553
Series B redeemable convertible preferred stock
Redeemable convertible preferred stock:
Total redeemable convertible preferred stock	$ 19,675	$ 22,420

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	27,836,869	27,836,869
Common stock, shares issued	5,583,405	4,575,867
Common stock, shares outstanding	5,583,405	4,575,867
Series A and A-1 redeemable convertible preferred stock
Redeemable convertible preferred stock, par value	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized	7,224,266	7,224,266
Redeemable convertible preferred stock, shares issued	6,911,766	6,911,766
Redeemable convertible preferred stock, shares outstanding	6,911,766	6,911,766
Liquidation preference	$ 6,884	$ 6,589
Series B redeemable convertible preferred stock
Redeemable convertible preferred stock, par value	$ 0.0001	$ 0.0001
Redeemable convertible preferred stock, shares authorized	3,548,614	3,548,614
Redeemable convertible preferred stock, shares issued	2,961,745	2,961,745
Redeemable convertible preferred stock, shares outstanding	2,961,745	2,961,745
Liquidation preference	$ 5,455	$ 5,223

UNAUDITED CONSOLIDATED STATEMEN

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
Product revenue	$ 20,731	$ 15,389	$ 58,732	$ 42,684
Service revenue	3,443	2,563	8,017	7,594
Total revenue	24,174	17,952	66,749	50,278
Cost of revenue, exclusive of depreciation and amortization shown below:
Product cost	15,951	11,461	44,103	32,811
Service cost	1,232	816	3,135	2,398
Total cost of revenue	17,183	12,277	47,238	35,209
Gross profit	6,991	5,675	19,511	15,069
Operating (income) expenses:
Research and development	1,028	693	2,878	1,879
Sales and marketing	881	703	2,511	2,071
General and administrative	2,053	2,084	5,762	5,374
Change in fair value of acquisition-related contingent consideration expense (income)	47	(330)	146	(1,348)
Depreciation and amortization	1,276	992	3,415	2,935
Total operating expenses	5,285	4,142	14,712	10,911
Income from operations	1,706	1,533	4,799	4,158
Other (income) expense:
Change in fair value of warrant liability	(626)	3,293	(639)	3,477
Interest expense	1,242	1,468	4,250	4,418
Loss on extinguishment of debt	1,396		1,396
Total other expense	2,012	4,761	5,007	7,895
Loss before income taxes	(306)	(3,228)	(208)	(3,737)
Income tax (benefit) expense	(164)	36	11	212
Net loss	(142)	(3,264)	(219)	(3,949)
Net income (loss) attributable to common stockholders
Net income (loss) attributable to common stockholders, basic	1,228	(14,066)	1,080	(16,007)
Net (loss) attributable to common stockholders, diluted	$ (803)	$ (14,066)	$ (894)	$ (16,007)
Net income (loss) per share attributable to common stockholders
Basic (in dollars per share)	$ 0.25	$ (3.21)	$ 0.22	$ (3.78)
Diluted (in dollars per share)	$ (0.08)	$ (3.21)	$ (0.09)	$ (3.78)
Weighted average common shares outstanding
Weighted average shares of common stock outstanding, basic	4,918,885	4,379,796	4,817,285	4,232,350
Weighted average shares of common stock outstanding, diluted	10,333,723	4,379,796	10,232,050	4,232,350

UNAUDITED CONSOLIDATED STATEME5

UNAUDITED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)shares
Increase (Decrease) in Temporary Equity
Balance at the beginning	$ 28,973
Accretion (decretion) of redeemable convertible preferred stock	(2,439)
Balance at the end	26,534
Series A redeemable convertible preferred stock
Increase (Decrease) in Temporary Equity
Balance at the beginning	$ 4,019
Balance at the beginning (in shares) | shares	4,411,766
Accretion (decretion) of redeemable convertible preferred stock	$ 188
Balance at the end	$ 4,207
Balance at the end (in shares) | shares	4,411,766
Series A-1 redeemable convertible preferred stock
Increase (Decrease) in Temporary Equity
Balance at the beginning	$ 2,534
Balance at the beginning (in shares) | shares	2,500,000
Accretion (decretion) of redeemable convertible preferred stock	$ 118
Balance at the end	$ 2,652
Balance at the end (in shares) | shares	2,500,000
Series B redeemable convertible preferred stock
Increase (Decrease) in Temporary Equity
Balance at the beginning	$ 22,420
Balance at the beginning (in shares) | shares	2,961,745
Accretion (decretion) of redeemable convertible preferred stock	$ (2,745)
Balance at the end	$ 19,675
Balance at the end (in shares) | shares	2,961,745

UNAUDITED CONSOLIDATED STATEME6

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - 9 months ended Sep. 30, 2016 - USD ($) $ in Thousands	Common StockClass A common stock	Common StockClass B common stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at beginning of period at Dec. 31, 2015				$ (31,628)	$ (31,628)
Balance at beginning of period (in shares) at Dec. 31, 2015	2,100,980	2,474,917
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with satisfaction of contingent consideration related to acquisition of St. Mary's Prescription Pharmacy			$ 35		35
Issuance of common stock in connection with satisfaction of contingent consideration related to acquisition of St. Mary's Prescription Pharmacy (in shares)	10,824
Accretion (decretion) of redeemable convertible preferred stock			(516)	2,955	2,439
Transfer of common stock(in shares)	2,577	(2,577)
Issuance of common stock (in shares)	1
Net exercise of stock warrants (in shares)		210,817
Net exercise of stock options (in shares)		63,220
Issuance of restricted stock (in shares)	722,646
Stock based compensation expense			$ 481		481
Net loss				(219)	(219)
Balance at end of period at Sep. 30, 2016				$ (28,892)	$ (28,892)
Balance at end of period (in shares) at Sep. 30, 2016	2,837,028	2,746,377

UNAUDITED CONSOLIDATED STATEME7

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (219)	$ (3,949)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	3,415	2,935
Amortization of deferred financing costs and debt discount	1,255	1,575
Payment of imputed interest on debt	(3,893)	(105)
Deferred taxes	(27)	212
Issuance of common stock warrants		16
Stock-based compensation	481	471
Change in fair value of warrant liability	(639)	3,477
Change in fair value of acquisition-related contingent consideration	146	(1,348)
Loss on extinguishment of debt	1,396
Other noncash items		(13)
Changes in operating assets and liabilities, net of effect from acquisitions:
Accounts receivable, net	(1,729)	(951)
Inventories	(305)	(353)
Rebates receivable	759	308
Prepaid expenses and other current assets	(114)	(191)
Other assets	(171)	79
Acquisition-related contingent consideration		(610)
Accounts payable	(191)	322
Accrued expenses and other liabilities	340	912
Other long-term liabilities	1,973	(4)
Net cash provided by operating activities	2,477	2,783
Cash flows from investing activities:
Purchases of property and equipment	(2,947)	(135)
Software development costs	(1,201)	(669)
Purchase of intangible assets	(29)
Change in restricted cash	200	300
Purchase of businesses, net of cash acquired	(1,000)	(2,403)
Net cash used in investing activities	(4,977)	(2,907)
Cash flows from financing activities:
Payments for debt financing costs	(1,521)	(69)
Repayments of notes payable to related parties		(354)
Borrowings on line of credit	6,000	10,000
Repayments of line of credit		(6,860)
Payments of acquisition-related consideration	(180)	(1,895)
Repayment of note payable related to acquisition	(14,337)
Payments of initial public offering costs	(2,191)	(390)
Payments of contingent consideration	(1,895)	(267)
Proceeds from long-term debt	30,000
Repayments of long-term debt	(13,609)	(1,605)
Net cash provided by (used in) financing activities	2,267	(1,440)
Net decrease in cash	(233)	(1,564)
Cash, beginning of period	2,026	4,122
Cash, end of period	1,793	2,558
Supplemental disclosure of cash flow information
Acquisition of equipment under capital leases	1,470	353
Additions to property, equipment, and software development purchases included in accounts payable	238	15
Deferred offering costs included in accounts payable	1,006	1,222
Cash paid for interest	7,901	1,807
(Decretion) accretion of redeemable convertible preferred stock to redemption value	$ (2,439)	$ 12,058

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2016
Nature of Business
Nature of Business	1. Nature of Business Tabula Rasa HealthCare, Inc. (the “Company”) provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The Company delivers its solutions through a comprehensive suite of technology-enabled products and services for medication risk management and risk adjustment. The Company serves healthcare organizations that focus on populations with complex healthcare needs and extensive medication requirements. The Company's suite of cloud-based software solutions provides prescribers, pharmacists and healthcare organizations with sophisticated and innovative tools to better manage the medication-related needs of patients. On October 4, 2016, the Company closed its initial public offering (the “IPO”) in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares of common stock, at an issuance price of $12.00 per share. The Company received net proceeds of $55,186 after deducting underwriting discounts and commissions of $4,154 but before deducting other offering expenses. In addition, upon the closing of the IPO, all of the Company’s then outstanding Class A Non-Voting common stock and Class B Voting common stock, totaling 5,583,405 shares, were automatically redesignated into shares of common stock, and all of the Company’s then outstanding convertible preferred stock converted into an aggregate of 5,089,436 shares of common stock. In addition, 202,061 shares of common stock were issued upon the automatic net exercise of outstanding warrants to purchase common stock that would have otherwise terminated immediately prior to the closing of the IPO. Additionally, in connection with the closing of the IPO, outstanding warrants to purchase shares of preferred stock converted into warrants to purchase an aggregate of 463,589 shares of common stock. Upon completion of the IPO on October 4, 2016, the Company filed an amended and restated certificate of incorporation to, among other things, state that the aggregate number of shares of stock that the Company is authorized to issue is 100,000,000 shares of common stock, par value $.0001 per share, and 10,000,000 shares of undesignated preferred stock, par value $.0001 per share.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The Company's significant accounting policies are disclosed in the Company’s audited consolidated financial statements for the year ended December 31, 2015, which is included in the Company’s final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on September 29, 2016 (the “Prospectus”) . Since the date of those audited consolidated financial statements, there have been no changes to the Company's significant accounting policies, including the status of recent accounting pronouncements, other than those detailed below. (a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2016 are not necessarily indicative of results to be expected for the year ending December 31, 2016, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Prospectus. (b) Reverse Stock Split The Company effected a 1-for-1.94 reverse split of its common stock on September 16, 2016. The reverse split combined each 1.94 shares of the Company's issued and outstanding common stock into one share of common stock and correspondingly adjusted the conversion prices of its convertible preferred stock. No fractional shares were issued in connection with the reverse split. Any fractional shares resulting from the reverse split were rounded down to the nearest whole share, and in lieu of any fractional shares the Company will pay a cash amount to the holder of such fractional share equal to the fair market value of such fractional share as determined by the Company’s board of directors (the “Board”). All share, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted, where applicable, to reflect the reverse stock split. (c) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $1,793 as of September 30, 2016, cash flows from operations, net proceeds from the IPO and borrowing availability under the Amended 2015 Revolving Line (Note 10) are sufficient to fund the Company's planned operations through at least March 31, 2018. (d) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions. (e) Deferred Offering Costs The Company capitalized certain legal, accounting and other third-party fees that were directly associated with the IPO as deferred offering costs (non-current). After the IPO on October 4, 2016 (Note 1 and 17), these costs were recorded in stockholders' deficit as a reduction of additional paid-in capital. Deferred offering costs were $3,677 and $2,298 as of September 30, 2016, and December 31, 2015, respectively. (f) Deferred Debt Issuance Costs Effective January 1, 2016, the Company adopted Accounting Standards Update (ASU) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the associated debt. Previously, the Company reported these costs in "Other assets" in the Company's consolidated balance sheets. The Company continues to defer the issuance costs related to its line of credit arrangement in "Other assets". The new guidance has been applied on a retrospective basis whereby prior-period financial statements have been adjusted to reflect the application of the new guidance, as required by the Financial Accounting Standards Board ("FASB") and resulted in the reclassification of $105 as of December 31, 2015 from other assets to current portion of long-term debt. (g) R ecent Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the disclosure impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements.

Net Income (Loss) per Share

Net Income (Loss) per Share	9 Months Ended
	Sep. 30, 2016
Net Income (Loss) per Share
Net Loss per Share	3. Net Income (Loss) per Share Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock of the Company outstanding during the period. The Company computed net income (loss) per share of common stock in conformity with the two-class method required for participating securities for the three and nine months ended September 30, 2016. The Company considers its redeemable convertible preferred stock to be participating securities as the holders of the preferred stock are entitled to receive a dividend in the event that a dividend is paid on common stock. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock during the period plus the impact of dilutive securities, to the extent that they are not anti-dilutive. The following table presents the calculation of basic and diluted net income (loss) per share for the Company’s common stock: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Numerator: Net loss $ $ $ $ Decretion (accretion) of redeemable convertible preferred stock Undistributed income attributable to redeemable convertible preferred stockholders — — Net income (loss) attributable to common stockholders, basic $ $ $ $ Decretion of redeemable convertible preferred stock — — Revaluation of warrant liability, net of tax — — Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — — Net (loss) attributable to common stockholders, diluted $ $ $ $ Denominator (basic): Weighted average shares of common stock outstanding, basic Denominator (diluted): Weighted average shares of common stock outstanding Effect of potential dilutive securities: Dilutive effect from preferred stock and preferred stock warrants assuming conversion — — Weighted average shares of common stock outstanding, diluted Net income (loss) per share attributable to common stockholders, basic $ $ $ $ Net (loss) per share attributable to common stockholders, diluted $ $ $ $ For the three and nine months ended September 30, 2016 and 2015, the Company's potential dilutive securities include stock options, restricted stock, outstanding warrants to purchase shares of preferred and common stock and redeemable convertible preferred stock, and have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Stock options to purchase common stock Restricted stock — — Common stock warrants Preferred stock warrants (as converted to common stock) — — Redeemable convertible preferred stock (as converted to common stock) — — On October 4, 2016, the Company closed its IPO in which the Company issued and sold 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares, at an issuance price of $12.00 per share. See Note 1 and Note 17 for additional information.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2016
Acquisition
Acquisition	4. Acquisition On September 15, 2016, the Company acquired certain assets, consisting primarily of intellectual property and software assets of 9176-1916 Quebec Inc. (an entity indirectly controlled by our Chief Scientific Officer, Jacques Turgeon). The intellectual property and software assets were previously licensed by us and are integrated into the Company’s Medication Risk Mitigation Matrix. The purchase price consisted of cash consideration of up to $6,000, consisting of $1,000 which was paid upon closing, $2,200 paid on November 2, 2016, $2,200 payable on the 45th business day following the completion the IPO and $600 following the 12-month anniversary of the closing date of the acquisition, which is contingent upon no claims for indemnification being made pursuant to the purchase agreement. In addition to the cash consideration, the purchase price included $5,000 worth of common stock, consisting of $2,500 of common stock due on the 31st business day following the completion of the IPO and $2,500 of common stock due on the 61st business day following the completion of the IPO. The stock consideration to be paid on the 31st and 61st business days following the completion of the IPO is calculated based on the arithmetic average of the daily volume-weighted average price of the Company’s common stock for the 30 business days ending on, and including, the 30th and 60th business day, respectively, following the completion of the IPO. The deferred acquisition cash consideration of $5,000 was recorded at its acquisition-date fair value of $4,955, using an assumed cost of debt of 7.8%. The $45 discount is being amortized to interest expense using the effective interest method through the consideration payment date. The Company amortized $2 of the discount to interest expense for the three and nine months ended September 30, 2016. Additionally, the deferred stock consideration of $5,000 was recorded at its acquisition-date fair value of $4,445. The stock consideration to be paid in connection with the acquisition is subject to a lock-up agreement and, as a result, a discount for lack of marketability of 10% was applied to determine the fair value of the stock consideration as of the acquisition date. These amounts are included in acquisition-related consideration payable in the consolidated balance sheets as of September 30, 2016. The assets acquired, and revenue generated from the acquired assets, are included in the Company’s consolidated financial statements from the date of acquisition. The following table summarizes the preliminary allocation of the purchase price based on the estimated fair values of the assets acquired at the date of acquisition: Developed technology $ Trade name Goodwill Total assets acquired $ The purchase price was allocated to identifiable intangible assets acquired based on their acquisition-date estimated fair values. The identifiable intangible assets principally included developed technology valued at $10,100 and trade name valued at $180, each of which are subject to amortization on a straight-line basis over 7 and 5 years, respectively. The weighted average amortization period for acquired intangible assets as of the date of acquisition is 6.96 years. The Company, with the assistance of a third-party appraiser, assessed the fair value of the assets. The fair value of the developed technology was estimated using a discounted present value income approach. To calculate fair value, the Company used cash flows discounted at a rate considered appropriate given the inherent risks associated with the intangible asset. The Company believes that the level and timing of cash flows appropriately reflect market participant assumptions. The fair value of the trade name was estimated using the relief from royalty method. The Company derived the hypothetical royalty income from the incremental projected revenues related to utilizing the acquired technology. The amortization of intangible assets is deductible for income tax purposes. The Company continues to evaluate the fair value of certain assets related to the acquisition. Additional information, which existed as of the acquisition date but was at that time unknown to the Company, may become known during the remainder of the measurement period. Changes to amounts recorded may result in a corresponding adjustment to goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year. The unaudited pro forma results presented below include the results of the 9176-1916 Quebec Inc. acquisition as if it had been consummated as of January 1, 2015. The unaudited pro forma results include the amortization associated with acquired intangible assets and interest expense on debt to fund the acquisition. Material nonrecurring charges directly attributable to the transactions are excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2015. Nine Months Ended September 30, 2016 2015 Revenue $ $ Net loss Net income (loss) per share attributable to common stockholders, basic Net (loss) per share attributable to common stockholders, diluted

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment Depreciation and amortization expense on property and equipment for the three months ended September 30, 2016 and 2015 was $359 and $250, respectively. Depreciation and amortization expense for the nine months ended September 30, 2016 and 2015 was $889 and $729, respectively.

Software Development Costs

Software Development Costs	9 Months Ended
	Sep. 30, 2016
Capitalized Computer Software, Net [Abstract]
Software Development Costs	6. Software Development Costs The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including external direct costs of material and services and payroll costs for employees directly involved with the software development. As of September 30, 2016 and December 31, 2015, gross capitalized software costs were $5,875 and $4,550 and accumulated amortization was $2,802 and $2,045, respectively. Amortization expense for the three months ended September 30, 2016 and 2015 was $302 and $164, respectively. Amortization expense for the nine months ended September 30, 2016 and 2015 was $757 and $474, respectively. As of September 30, 2016 and December 31, 2015, there was $1,136 and $888, respectively, of capitalized software costs that were not yet subject to amortization.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	7. Goodwill and Intangible Assets The Company’s goodwill and related changes during the nine months ended September 30, 2016 are as follows: Balance at January 1, 2016 $ Goodwill from 2016 acquisition Balance at September 30, 2016 $ Intangible assets consisted of the following as of September 30, 2016 and December 31, 2015: Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net September 30, 2016 Trade names 5.00 $ $ $ Client relationships 10.02 Non-competition agreements 4.64 Developed technology 7.76 Domain name 10.00 Total intangible assets $ $ $ Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2015 Trade names 5.00 $ $ $ Client relationships 10.02 Non-competition agreements 4.64 Developed technology 10.00 Total intangible assets $ $ $ Amortization expense for intangible assets for the three months ended September 30, 2016 and 2015 was $614 and $577, respectively. Amortization expense for the nine months ended September 30, 2016 and 2015 was $1,767 and $1,730, respectively. The estimated amortization expense for each of the next five years and thereafter is as follows: Years Ending December 31, 2016 (October 1- December 31) $ 2017 2018 2019 2020 Thereafter $

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities and Other Liabilities
Accrued Expenses and Other Liabilities	8. Accrued Expenses and Other Liabilities At September 30, 2016 and December 31, 2015, accrued expenses and other liabilities consisted of the following: September 30, 2016 December 31, 2015 Employee related expenses $ $ Deferred revenue Interest Deferred rent Other expenses Total accrued expenses and other liabilities $ $

Notes Payable Related to Acquis

Notes Payable Related to Acquisition	9 Months Ended
	Sep. 30, 2016
Notes Payable Related to Acquisition
Notes Payable Related to Acquisition	9. Notes Payable Related to Acquisition In December 2014, the Company acquired all of the authorized, issued and outstanding equity interests of Medliance LLC ("Medliance"), which provides pharmacy cost management services through data analytics. As part of the acquisition-related consideration of the Medliance acquisition, the Company issued multiple subordinated convertible promissory notes (the "Medliance Notes") to the owners of Medliance for aggregate borrowings of $16,385. Interest was 8% and compounded annually. All unpaid principal and unpaid and accrued interest was due and payable on June 30, 2016. On July 1, 2016, the Company repaid the Medliance Notes with the proceeds from a long-term credit facility (see Note 10). Interest expense was $330 for the three months ended September 30, 2015. Interest expense was $706 and $980 for the nine months ended September 30, 2016 and 2015, respectively. The Company recorded the Medliance Notes at their aggregate acquisition date fair values of $14,347 and the notes were accreted up to their face values of $16,385 over the 18 month term using the effective-interest method. For the three months ended September 30, 2015, the Company amortized $325 of the discount to interest expense. For the nine months ended September 30, 2016 and 2015, the Company amortized $755 and $906, respectively, of the discount to interest expense.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	9 Months Ended
	Sep. 30, 2016
Lines of Credit and Long-Term Debt
Lines of Credit and Long-Term Debt	10. Lines of Credit and Long-Term Debt (a) Lines of Credit On April 29, 2015, the Company entered into a new revolving line of credit (the "2015 Revolving Line") with Bridge Bank, National Association ("Bridge Bank") pursuant to a loan and security agreement, which provided for borrowings in an aggregate amount up to $15,000 to be used for general corporate purposes including repayment of the previous Revolving Line. On July 1, 2016, the Company entered into a Loan and Security Modification Agreement (the "Amended 2015 Revolving Line") with Western Alliance Bank, successor in interest to Bridge Bank, whereby the 2015 Revolving Line was amended to increase the Company's borrowing availability to up to $25,000 and extend the maturity date to July 1, 2018. The Company's ability to borrow under the Amended 2015 Revolving Line is based upon a specified borrowing base equal to the Company's trailing four months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, through June 30, 2017 and based upon the Company's trailing three months of monthly recurring revenue, as defined, from eligible recurring revenue contracts, as defined, thereafter. Interest on the Amended 2015 Revolving Line was also amended to be calculated at a variable rate based upon Western Alliance Bank's prime rate plus 1.0%, with Western Alliance Bank's prime rate having a floor of 3.5%. Financial covenants under the Amended 2015 Revolving Line require that the Company (i) maintain an unrestricted cash and unused availability balance under the Amended 2015 Revolving Line of at least $3,000 at all times (the liquidity covenant), (ii) maintain a minimum EBITDA, as defined, of $2,000 for the quarter ending June 30, 2016, $2,250 for the quarter ending September 30, 2016, and $2,500 for the quarter ending December 31, 2016 and thereafter, and (iii) maintain a minimum monthly recurring revenue retention rate of at least 90%, measured quarterly. As of September 30, 2016, the Company was in compliance with all of the financial covenants related to the 2015 Amended Revolving Line, and management expects that the Company will be able to maintain compliance with the financial covenants. As of September 30, 2016, the aggregate borrowings outstanding under the Amended 2015 Revolving Line was $16,000, and additional amounts available for borrowings under the Amended 2015 Revolving Line was $9,000. As of September 30, 2016, the interest rate on the Amended 2015 Revolving Line was 4.56% and interest expense was $169 and $109 for the three months ended September 30, 2016 and 2015, respectively, and $449 and $181 for the nine months ended September 30, 2016 and 2015, respectively. In connection with the 2015 Revolving Line and the Amended 2015 Revolving Line, the Company recorded deferred financing costs of $141. The Company is amortizing the deferred financing costs associated with the 2015 Revolving Line to interest expense using the effective-interest method over the term of the Amended 2015 Revolving Line and amortized $9 and $13 to interest expense for the three months ended September 30, 2016 and 2015, respectively, and $36 and $22 for the nine months ended September 30, 2016 and 2015, respectively. (b) Term Loan On July 1, 2016, the Company entered into a term loan facility (the “ABC Credit Facility”) with ABC Funding, LLC, an affiliate of Summit Partners, L.P. (“Summit”). The proceeds of the initial term loan advance of $30,000 under the ABC Credit Facility were used to repay all outstanding principal and interest under the Medliance Notes, as well as loans entered into with Eastward Capital Partners V, L.P. and its affiliates in April 2014 and December 2014 with an original principal balance of $15,000 (collectively, the “Eastward Loans”) . For the three and nine months ended September 30, 2016, the Company recognized a $1,396 loss on extinguishment of debt as a result of a prepayment premium and the recognition of the remaining unamortized discounts and finance costs on the Eastward Loans. Amounts outstanding under the ABC Credit Facility bore interest at a per annum rate equal to 12.0% payable monthly in arrears. Interest expense under the ABC Credit Facility was $920 for the three and nine months ended September 30, 2016. The ABC Credit Facility had a maturity date of December 30, 2021, and was secured by a subordinated security interest in all personal property, whether presently existing or created or acquired in the future, as well as the Company's intellectual property. The Company recorded $1,487 in deferred financing costs associated with the ABC Credit Facility and is amortizing the deferred financing costs to interest expense using the effective-interest method over the term of the ABC Credit Facility. The Company amortized $66 to interest expense for the three and nine months ended September 31, 2016. As of September 30, 2016, the aggregate borrowing outstanding under the ABC Credit Facility was $30,000. On October 4, 2016, the Company repaid all the then outstanding principal and interest on the ABC Credit Facility, as well as a prepayment penalty of $3,597, with proceeds received from the IPO and, in connection with such repayment, the ABC Credit Facility was terminated. The Company will record a loss on debt extinguishment of $5,015 in the fourth quarter of 2016 related to the settlement of the ABC Credit Facility for the prepayment penalty plus the amortization of the deferred financing costs. (c) Term Loans and Capital Lease Obligations The following table represents the total term loans and capital lease obligations of the Company at September 30, 2016 and December 31, 2015: September 30, 2016 December 31, 2015 Tranche A Term Loan $ — $ Tranche B Term Loan — April 2014 Eastward Loan — Unamortized finance costs on April 2014 Eastward Loan — Unamortized discount on April 2014 Eastward Loan — April 2014 Eastward Loan, net — December 2014 Eastward Loan — Unamortized finance costs on December 2014 Eastward Loan — Unamortized discount on December 2014 Eastward Loan — December 2014 Eastward Loan, net — ABC Credit Facility — Unamortized finance costs on ABC Credit Facility — ABC Credit Facility, net — Capital leases Total long-term debt, net $ $ Less current portion, net Total long-term debt, less current portion, net $ $ (d) Long-Term Debt Maturities As of September 30, 2016, the Company's long-term debt is payable as follows: Total Capital lease long-term Term Loans obligations debt Remainder of 2016 $ $ $ 2017 — 2018 — 2019 — 2020 — 2020 — Less amount representing interest — Present value of payments Less current portion Less discount on debt — $ — $ $ (e) Other Financing In May 2016, the Company signed a prime vendor agreement with AmerisourceBergen Drug Corporation, which was effective March 2016 and requires a monthly minimum purchase obligation of approximately $1,750. The Company fully expects to meet this requirement. This agreement was subsequently amended and restated effective May 1, 2016 with a three-year term expiring April 2019. As of September 30, 2016 and December 31, 2015, the Company had $3,190 and $3,691, respectively, due to AmerisourceBergen Drug Corporation as a result of prescription drug purchases.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Taxes
Income Taxes	11. Income Taxes For the nine months ended September 30, 2016 and 2015, the Company recognized tax expense of $11 , which resulted in an effective tax rate of (5.3)%, and tax expense of $212 thousand, which resulted in an effective tax rate of (5.7%), respectively, primarily related to deferred tax expense associated with indefinite-lived deferred tax liabilities for goodwill amortization. The Company has recorded a full valuation allowance against its deferred tax assets at September 30, 2016 and December 31, 2015.

Other Long-term Liabilities

Other Long-term Liabilities	9 Months Ended
	Sep. 30, 2016
Other Long-term Liabilities
Other Long-term Liabilities	12. Other Long-term Liabilities Other long term liabilities as of September 30, 2016 consisted of $1,973, which represents the long-term portion of deferred rent related to the Company's new operating leases for office space in Moorestown, NJ.

Stockholders' Deficit and Redee

Stockholders' Deficit and Redeemable Convertible Preferred Stock	9 Months Ended
	Sep. 30, 2016
Stockholders' Deficit and Redeemable Convertible Preferred Stock
Stockholders' Deficit and Redeemable Convertible Preferred Stock	13. Stockholders' Deficit and Redeemable Convertible Preferred Stock (a) Common Stock The holders of Class A Non-Voting common stock have the same rights, preferences, privileges, and restrictions as the holders of Class B Voting common stock with the exception of voting rights. The holders of Class B Voting common stock are entitled to one vote per share. The holders of Class A Non-Voting and Class B Voting common stock are entitled to receive dividends when, as and if declared by the Board, subject to payment of accrued dividends for redeemable convertible preferred stock. Class A Non-Voting and Class B Voting common stock are also subordinate to the redeemable convertible preferred stock with respect to liquidation, winding up and dissolution of the Company. No dividends have been declared through September 30, 2016. The Class A Non-Voting and Class B Voting common stock were redesignated into shares of common stock upon the closing of the IPO (Note 1 and 17). (b) Redeemable Convertible Preferred Stock The Company has issued Series A, Series A-1, and Series B redeemable convertible preferred stock. The redeemable convertible preferred stock is classified outside of stockholders' deficit because the shares contain redemption features that are not solely within the control of the Company. The aggregate amount of cumulative but unpaid dividends on the Series A and Series A-1 redeemable convertible preferred stock were $1,223 and $661, respectively, at September 30, 2016. Cumulative but unpaid dividends on the Series B redeemable convertible preferred stock were $944 at September 30, 2016. The redemption value of Series B redeemable convertible preferred stock is based on its estimated fair value at September 30, 2016 because it is estimated to be greater than its original issue price plus accrued dividends. On September 16, 2016, the Company amended the conversion feature of the Series A, Series A-1, and Series B redeemable convertible preferred stock to provide that such shares of preferred stock would also automatically convert in connection with the IPO. Upon the closing of the IPO, such shares of redeemable convertible preferred stock converted into shares of the Company’s common stock (Note 1 and 17). (c) Common Stock Warrants As of September 30, 2016, the following warrants to purchase common stock were outstanding: Warrants Number Exercise to Purchase of Warrants Price Term Expiration Common-A $ 10 year May - October 2019 Common-B $ 10 year May - October 2019 Common-A $ 10 year May 2019 Common-A $ 10 year December 2019 Common-A $ 10 year March 2020 Common-B $ 10 year June 2021 Common-B $ 10 year May - December 2023 Common-B $ 10 year January - December 2024 During the nine months ended September 30, 2015, the Company issued warrants to purchase 4,485 shares of common stock at an exercise price of $6.40 per share in connection with related party debt. The Company recognized total interest expense of $16 associated with the equity-classified warrants issued during the nine months ended September 30, 2015. No warrants were issued during the nine months ended September 30, 2016 and no interest expense was recognized during 2016. During the nine months ended September 30, 2016, the Company issued 210,817 shares of common stock upon the cashless exercise of warrants to purchase 232,787 shares of common stock. Upon completion of the IPO on October 4, 2016, all outstanding warrants to purchase common stock were automatically net exercised (Note 1 and 17). The warrants issued during the nine months ended September 30, 2015 were valued using the Black-Scholes option-pricing model at the date of grant, and included the following weighted average assumptions: Nine Months Ended Valuation assumptions: September 30, 2015 Expected volatility Expected life (years) Risk-free interest rate Dividend yield — (d) Preferred Stock Warrants As of September 30, 2016, the following warrants to purchase redeemable convertible preferred stock were outstanding: Warrants Number Exercise to Purchase of Warrants Price Term Expiration Series A-1 250,000 $ 10 year March 2022 Series A-1 62,500 $ 10 year October 2022 Series B 105,005 $ 10 year April 2024 Series B 481,863 $ 10 year December 2024 No preferred stock warrants were issued during the nine months ended September 30, 2016 and 2015. Upon completion of the IPO on October 4, 2016, outstanding warrants to purchase preferred stock converted into warrants to purchase an aggregate of 463,589 shares of common stock (Note 1 and 17).

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2016
Stock-Based Compensation
Stock-Based Compensation	14. Stock-Based Compensation The Company's Amended and Restated 2014 Equity Compensation Plan (the "2014 Plan") authorizes the Company to grant up to 3,935,865 shares of common stock to the Company's employees and non-employees in the form of incentive stock options, nonqualified stock options, stock awards, stock units, stock appreciation rights, and other equity-based awards. In September 2016, the Board approved an increase in the shares of common stock authorized under the 2014 Plan to 4,037,981. This pool consists of 2,702,443 shares of Class A common stock and 1,335,538 shares of Class B common stock. In September 2016, the Company adopted the 2016 Equity Compensation Plan (the “2016 Plan”) and merged the 2014 Plan into the 2016 Plan on September 28, 2016. No additional grants were made thereafter under the 2014 Plan. Outstanding grants under the 2014 Plan will continue in effect according to their terms as in effect before the merger with the 2016 Plan, and the shares with respect to outstanding grants under the 2014 Equity Plan will be issued or transferred under the 2016 Plan. The 2016 Plan authorizes the issuance or transfer of up to the sum of the following: (1) 800,000 new shares, plus (2) the number of shares of our common stock subject to outstanding grants under the 2014 Equity Plan as of the effective date of the 2016 Plan; provided, however, that the aggregate number of shares of the Company’s common stock that may be issued or transferred under the 2016 Plan pursuant to incentive stock options may not exceed 800,000. During the term of the 2016 Plan, the share reserve will automatically increase on the first trading day in January of each calendar year, beginning in calendar year 2017, by an amount equal to the lesser of 5% of the total number of outstanding shares of common stock on the last trading day in December of the prior calendar year or such other number set by our Board. As of September 30, 2016, 777,740 shares were available for future grants under the 2016 Plan. On September 28, 2016, the Board granted 700,386 shares of restricted common stock to certain Company employees, including executive officers, under the 2014 Plan, prior to merging it with the 2016 Plan, pursuant to a special equity award pool previously approved by the Board which was made immediately prior to the effectiveness of the Company's registration statement filed in connection with the Company's IPO. All shares of restricted common stock will vest in full on May 31, 2017. The value of the grants is based on the IPO price of $12.00 per share and the related non-cash compensation expense will be recognized ratably over the vesting period from the date of grant through May 31, 2017, when the shares underlying the grant fully vest. For the three and nine months ended September 30, 2016, $102 of expense was recognized related to this grant. As of September 30, 2016, there was unrecognized compensation expense of $8,302 related to this grant. On September 28, 2016, the Company granted 22,260 shares of restricted common stock under the 2016 Plan to our non-employee directors, which represents both the initial and annual grants to such directors. The initial grant will vest in three substantially equal annual installments over three years following the grant date and the annual grant will vest in full on the earlier of the next annual shareholder meeting or the one year anniversary of the grant date. The value of the grants is based on the IPO price of $12.00. For the three and nine months ended September 30, 2016, $1 of expense was recognized related to these grants. As of September 30, 2016, there was unrecognized compensation expense of $266 related to these grants. In addition, in September 2016 the Board approved the issuance of 13,362 shares of common stock, net of 7,010 shares of common stock withheld for tax withholding purposes, to certain executive officers upon the closing of the IPO pursuant to a Leadership Exit Bonus Plan and under the 2016 Plan. The value of the issuance is based upon the IPO price of $12.00 per share. As of September 30, 2016, no shares have been issued. The Company recorded $120 and $159 of stock-based compensation expense related to the vesting of employee and non-employee stock options for the three months ended September 30, 2016 and 2015, respectively. The Company recorded $378 and $471 of stock-based compensation expense related to the vesting of employee and non-employee stock options for the nine months ended September 30, 2016 and 2015, respectively. The estimated fair value of options granted was calculated using a Black- Scholes option-pricing model. The computation of expected life for employees was determined based on the simplified method. The risk-free rate is based on the U.S. Treasury security with terms equal to the expected time of exercise as of the grant date. The Company's common stock had not been publicly traded until the IPO commenced on September 29, 2016; therefore, expected volatility is based on the historical volatilities of selected public companies whose services are comparable to that of the Company. The table below sets forth the weighted average assumptions for employee grants during the nine months ended September 30, 2016 and 2015: Nine Months Ended September 30, Valuation assumptions: 2016 2015 Expected volatility % % Expected life (years) Risk-free interest rate % % Dividend yield — — The following table summarizes stock option activity under the 2016 Plan for the nine months ended September 30, 2016: Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at January 1, 2016 $ $ Granted Exercised Forfeited Outstanding at September 30, 2016 $ $ Options vested and expected to vest at September 30, 2016 $ $ Exercisable at September 30, 2016 $ $ Included within the above table are 217,747 non-employee options outstanding as of September 30, 2016, of which 2,446 are unvested as of September 30, 2016 and therefore subject to remeasurement. The weighted average grant date fair value of employee options granted during the nine months ended September 30, 2016 and 2015 was $7.29 and $3.23, respectively. The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the estimated fair value of the Company's common stock as of September 30, 2016 for those stock options that had exercise prices lower than the fair value of the Company's common stock. As of September 30, 2016, there was $906 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 1.5 years. The Company recorded total stock-based compensation expense for the three and nine months ended September 30, 2016 and 2015, in the following expense categories of its consolidated statement of operations: Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Cost of revenue - product $ $ $ $ Cost of revenue - service Research and development Sales and marketing General and administrative $ $ $ $

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Measurements
Fair Value Measurements	15. Fair Value Measurements The Company’s financial instruments consist of accounts receivable, accounts payable, accrued expenses, acquisition-related contingent consideration, notes payable related to acquisition, notes payable to related parties, and long-term debt. The carrying values of accounts receivable, accounts payable and accrued expenses are representative of their fair value due to the relatively short-term nature of those instruments. The carrying value of the Company’s long-term debt approximates fair value based on the terms of the debt. The notes payable related to acquisition were recorded on December 31, 2014 at their acquisition date fair values of $14,347. This valuation was determined using Level 3 inputs. The note was fully repaid on July 1, 2016 (see Note 9). The Company has classified liabilities measured at fair value on a recurring basis at September 30, 2016 and December 31, 2015 as follows: Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 September 30, 2016 Liabilities Warrant liability $ — $ — $ $ Acquisition-related contingent consideration - short-term — — Acquisition-related contingent consideration - long-term — — $ — $ — $ $ Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2015 Liabilities Warrant liability $ — $ — $ $ Note payable related to acquisition — — Acquisition-related contingent consideration - short-term — — Acquisition-related contingent consideration - long-term — — $ — $ — $ $ The fair value of the preferred stock warrants at September 30, 2016 was estimated using an option pricing model with the following weighted average assumptions: estimated life of 7.24 years, no dividend yield, risk-free interest rate of 1.40%, fair value of underlying instrument of $14.32 per share, and volatility of 59.69%. The Company also applied a discount for lack of marketability of 10% to the resulting value from the option pricing model. The fair value of the preferred stock warrants at December 31, 2015 was estimated using an option pricing model with the following weighted average assumptions: estimated life of 7.99 years, no dividend yield, risk-free interest rate of 2.10%, fair value of underlying instrument of $8.14 per share and volatility of 57.81%. The Company also applied a discount for lack of marketability of 10% to the resulting value from the option pricing model. The Company developed its own assumptions that do not have observable inputs or available market data to support the fair value. This method of valuation involves using inputs such as the fair value of the Company’s various classes of preferred stock, stock price volatility, the contractual term of the warrants, risk-free interest rates, and dividend yields. Due to the nature of these inputs, the valuation of the warrants is considered a Level 3 measurement. The Company accounts for its redeemable convertible preferred stock warrants as liabilities in accordance with the guidance for accounting for certain financial instruments with characteristics of both liabilities and equity, as warrants entitle the holder to purchase preferred stock that is considered contingently redeemable. The warrant liability is recorded on its own line item on the Company’s consolidated balance sheets. The warrant liability is marked-to-market each reporting period with the change in fair value recorded on its own line in the consolidated statements of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified as an equity instrument. The reconciliation of the warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Balance at January 1, 2016 $ Change in fair value Balance at September 30, 2016 $ Acquisition-related contingent consideration is measured at fair value on a recurring basis using unobservable inputs, hence these instruments represent Level 3 measurements within the fair value hierarchy. The acquisition-related contingent consideration liability represents the estimated fair value of the additional cash consideration payable that is contingent upon the achievement of certain financial and performance milestones. The changes in fair value of the Company’s acquisition-related contingent consideration for the nine months ended September 30, 2016 was as follows: Balance at January 1, 2016 $ Fair value of cash consideration paid Adjustments to fair value measurement Balance at September 30, 2016 $

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Sep. 30, 2016
Related-Party Transactions
Related-Party Transactions	16. Related-Party Transactions As of September 30, 2016 and December 31, 2015, there was a demand promissory note with a stockholder with a balance outstanding of $250, which bears interest at 6% annually. During 2015, certain other related-party borrowings from the Company's executive officers were outstanding. Such other amounts were fully repaid as of September 30, 2016 and December 31, 2015. Total interest expense from these related-party borrowings was $4 and $10 for the three months ended September 30, 2016 and 2015, respectively, and $11 and $38 for the nine months ended September 30, 2016 and 2015, respectively. The demand promissory note was repaid in full in October 2016 with the proceeds from the IPO. On September 15, 2016, the Company acquired certain assets from an entity indirectly controlled by the Company’s Chief Scientific Officer (Note 4).

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2016
Subsequent Events
Subsequent Events	17. Subsequent Events On October 4, 2016, the Company completed its IPO pursuant to which the Company issued 4,300,000 shares of common stock, plus the exercise of the underwriters’ option to purchase an additional 645,000 shares, at an IPO price of $12.00 per share (Note 1). In October 2016, 13,362 shares of common stock, net of 7,010 shares of common stock withheld for tax withholding purposes, were issued to certain executive officers pursuant to the Leadership Exit Bonus Plan and under the 2016 Plan. The value of this issuance is $244 based upon the IPO price of $12.00 per share and the non-cash compensation charge will be recognized in the fourth quarter of 2016 as all shares issued will be fully vested upon issuance. Also in October 2016, 202,061 shares of common stock were issued upon the automatic net exercise of outstanding warrants that would otherwise have expired upon the completion of the IPO, immediately prior to the closing of the IPO. In addition, outstanding warrants to purchase preferred stock converted into warrants to purchase an aggregate of 463,589 shares of common stock (Note 1), and on October 12, 2016, 288,324 shares of common stock were issued upon the net exercise of 431,373 of these warrants.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Summary of Significant Accounting Policies
Basis of Presentation	(a) Basis of Presentation The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments ( consisting of normal recurring accruals and adjustments) , necessary for the fair statement of the Company's interim consolidated financial position for the periods indicated. The interim results for the three and nine months ended September 30, 2016 are not necessarily indicative of results to be expected for the year ending December 31, 2016, any other interim periods, or any future year or period. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Prospectus.
Reverse Stock Split	(b) Reverse Stock Split The Company effected a 1-for-1.94 reverse split of its common stock on September 16, 2016. The reverse split combined each 1.94 shares of the Company's issued and outstanding common stock into one share of common stock and correspondingly adjusted the conversion prices of its convertible preferred stock. No fractional shares were issued in connection with the reverse split. Any fractional shares resulting from the reverse split were rounded down to the nearest whole share, and in lieu of any fractional shares the Company will pay a cash amount to the holder of such fractional share equal to the fair market value of such fractional share as determined by the Company’s board of directors (the “Board”). All share, per share and related information presented in the consolidated financial statements and accompanying notes have been retroactively adjusted, where applicable, to reflect the reverse stock split.
Liquidity	(c) Liquidity The Company's unaudited consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities in the ordinary course of business. Management believes that the Company's cash on hand of $1,793 as of September 30, 2016, cash flows from operations, net proceeds from the IPO and borrowing availability under the Amended 2015 Revolving Line (Note 10) are sufficient to fund the Company's planned operations through at least March 31, 2018.
Use of Estimates	(d) Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates or assumptions.
Deferred Offering Costs	(e) Deferred Offering Costs The Company capitalized certain legal, accounting and other third-party fees that were directly associated with the IPO as deferred offering costs (non-current). After the IPO on October 4, 2016 (Note 1 and 17), these costs were recorded in stockholders' deficit as a reduction of additional paid-in capital. Deferred offering costs were $3,677 and $2,298 as of September 30, 2016, and December 31, 2015, respectively.
Deferred Debt Issuance Costs	(f) Deferred Debt Issuance Costs Effective January 1, 2016, the Company adopted Accounting Standards Update (ASU) No. 2015-03, Simplifying the Presentation of Debt Issuance Costs , which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the associated debt. Previously, the Company reported these costs in "Other assets" in the Company's consolidated balance sheets. The Company continues to defer the issuance costs related to its line of credit arrangement in "Other assets". The new guidance has been applied on a retrospective basis whereby prior-period financial statements have been adjusted to reflect the application of the new guidance, as required by the Financial Accounting Standards Board ("FASB") and resulted in the reclassification of $105 as of December 31, 2015 from other assets to current portion of long-term debt.
Recent Accounting Pronouncements	(g) R ecent Accounting Pronouncements In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments ("ASU 2016-15"). ASU 2016-15 provides new guidance to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. ASU 2016-15 is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company is currently evaluating the disclosure impact of the adoption of ASU 2016-15 on the Company's consolidated financial statements.
Earnings Per Share	Basic net income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average number of shares of common stock of the Company outstanding during the period. The Company computed net income (loss) per share of common stock in conformity with the two-class method required for participating securities for the three and nine months ended September 30, 2016. The Company considers its redeemable convertible preferred stock to be participating securities as the holders of the preferred stock are entitled to receive a dividend in the event that a dividend is paid on common stock. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock during the period plus the impact of dilutive securities, to the extent that they are not anti-dilutive.

Net Income (Loss) per Share (Ta

Net Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Net Income (Loss) per Share
Schedule of calculation of basic and diluted net loss per share	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Numerator: Net loss $ $ $ $ Decretion (accretion) of redeemable convertible preferred stock Undistributed income attributable to redeemable convertible preferred stockholders — — Net income (loss) attributable to common stockholders, basic $ $ $ $ Decretion of redeemable convertible preferred stock — — Revaluation of warrant liability, net of tax — — Adjustment to undistributed income attributable to redeemable convertible preferred stockholders — — Net (loss) attributable to common stockholders, diluted $ $ $ $ Denominator (basic): Weighted average shares of common stock outstanding, basic Denominator (diluted): Weighted average shares of common stock outstanding Effect of potential dilutive securities: Dilutive effect from preferred stock and preferred stock warrants assuming conversion — — Weighted average shares of common stock outstanding, diluted Net income (loss) per share attributable to common stockholders, basic $ $ $ $ Net (loss) per share attributable to common stockholders, diluted $ $ $ $
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Stock options to purchase common stock Restricted stock — — Common stock warrants Preferred stock warrants (as converted to common stock) — — Redeemable convertible preferred stock (as converted to common stock) — —

Acquisition (Tables)

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2016
Acquisition
Schedule of allocation of the purchase price based on the estimated fair values of the assets acquired and liabilities	Developed technology $ Trade name Goodwill Total assets acquired $
Business Acquisition, Pro Forma Information [Table Text Block]	Nine Months Ended September 30, 2016 2015 Revenue $ $ Net loss Net income (loss) per share attributable to common stockholders, basic Net (loss) per share attributable to common stockholders, diluted

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Balance at January 1, 2016 $ Goodwill from 2016 acquisition Balance at September 30, 2016 $
Schedule of intangible assets	Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net September 30, 2016 Trade names 5.00 $ $ $ Client relationships 10.02 Non-competition agreements 4.64 Developed technology 7.76 Domain name 10.00 Total intangible assets $ $ $ Weighted Average Amortization Period Accumulated Intangible (in years) Gross Value Amortization Assets, net December 31, 2015 Trade names 5.00 $ $ $ Client relationships 10.02 Non-competition agreements 4.64 Developed technology 10.00 Total intangible assets $ $ $
Schedule of estimated amortization expense	Years Ending December 31, 2016 (October 1- December 31) $ 2017 2018 2019 2020 Thereafter $

Accrued Expenses and Other Li29

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2016
Accrued Liabilities and Other Liabilities
Schedule of accrued expenses and other liabilities	September 30, 2016 December 31, 2015 Employee related expenses $ $ Deferred revenue Interest Deferred rent Other expenses Total accrued expenses and other liabilities $ $

Lines of Credit and Long-Term30

Lines of Credit and Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Lines of Credit and Long-Term Debt
Schedule of total term loans and capital lease obligations	September 30, 2016 December 31, 2015 Tranche A Term Loan $ — $ Tranche B Term Loan — April 2014 Eastward Loan — Unamortized finance costs on April 2014 Eastward Loan — Unamortized discount on April 2014 Eastward Loan — April 2014 Eastward Loan, net — December 2014 Eastward Loan — Unamortized finance costs on December 2014 Eastward Loan — Unamortized discount on December 2014 Eastward Loan — December 2014 Eastward Loan, net — ABC Credit Facility — Unamortized finance costs on ABC Credit Facility — ABC Credit Facility, net — Capital leases Total long-term debt, net $ $ Less current portion, net Total long-term debt, less current portion, net $ $
Schedule of maturities of long-term debt payable	As of September 30, 2016, the Company's long-term debt is payable as follows: Total Capital lease long-term Term Loans obligations debt Remainder of 2016 $ $ $ 2017 — 2018 — 2019 — 2020 — 2020 — Less amount representing interest — Present value of payments Less current portion Less discount on debt — $ — $ $

Stockholders' Deficit and Red31

Stockholders' Deficit and Redeemable Convertible Preferred Stock (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of valuation assumptions for warrants issued using Black-Scholes option-pricing model	Nine Months Ended Valuation assumptions: September 30, 2015 Expected volatility Expected life (years) Risk-free interest rate Dividend yield —
Common stock warrants
Schedule of warrants to purchase stock	As of September 30, 2016, the following warrants to purchase common stock were outstanding: Warrants Number Exercise to Purchase of Warrants Price Term Expiration Common-A $ 10 year May - October 2019 Common-B $ 10 year May - October 2019 Common-A $ 10 year May 2019 Common-A $ 10 year December 2019 Common-A $ 10 year March 2020 Common-B $ 10 year June 2021 Common-B $ 10 year May - December 2023 Common-B $ 10 year January - December 2024
Preferred stock warrants
Schedule of warrants to purchase stock	As of September 30, 2016, the following warrants to purchase redeemable convertible preferred stock were outstanding: Warrants Number Exercise to Purchase of Warrants Price Term Expiration Series A-1 250,000 $ 10 year March 2022 Series A-1 62,500 $ 10 year October 2022 Series B 105,005 $ 10 year April 2024 Series B 481,863 $ 10 year December 2024

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Stock-Based Compensation
Schedule of weighted average assumptions for employee grants	Nine Months Ended September 30, Valuation assumptions: 2016 2015 Expected volatility % % Expected life (years) Risk-free interest rate % % Dividend yield — —
Summary of stock option activity	Weighted Weighted average average remaining Aggregate Number exercise contractual intrinsic of shares price term value Outstanding at January 1, 2016 $ $ Granted Exercised Forfeited Outstanding at September 30, 2016 $ $ Options vested and expected to vest at September 30, 2016 $ $ Exercisable at September 30, 2016 $ $
Schedule of recorded stock-based compensation expense related to stock options	Three Months Ended Nine Months Ended September 30, September 30, 2016 2015 2016 2015 Cost of revenue - product $ $ $ $ Cost of revenue - service Research and development Sales and marketing General and administrative $ $ $ $

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Change in fair value
Schedule of classified liabilities measured at fair value on recurring basis	Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 September 30, 2016 Liabilities Warrant liability $ — $ — $ $ Acquisition-related contingent consideration - short-term — — Acquisition-related contingent consideration - long-term — — $ — $ — $ $ Fair Value Measurement at Reporting Date Using Balance as of Level 1 Level 2 Level 3 December 31, 2015 Liabilities Warrant liability $ — $ — $ $ Note payable related to acquisition — — Acquisition-related contingent consideration - short-term — — Acquisition-related contingent consideration - long-term — — $ — $ — $ $
Warrant liability
Change in fair value
Schedule of reconciliation of liability measured at fair value on recurring basis using significant unobservable inputs (Level 3)	Balance at January 1, 2016 $ Change in fair value Balance at September 30, 2016 $
Acquisition related contingent consideration
Change in fair value
Schedule of reconciliation of liability measured at fair value on recurring basis using significant unobservable inputs (Level 3)	Balance at January 1, 2016 $ Fair value of cash consideration paid Adjustments to fair value measurement Balance at September 30, 2016 $

Nature of Business (Details)

Nature of Business (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 12, 2016	Oct. 04, 2016	Sep. 30, 2016	Oct. 03, 2016	Dec. 31, 2015	Sep. 30, 2015
Initial Public Offering
Outstanding common stock (in shares)			5,583,405		4,575,867
Shares of common stock, authorized			27,836,869		27,836,869
Shares of common stock, par value (in dollars per share)			$ 0.0001		$ 0.0001
Common stock warrants
Initial Public Offering
Shares issued upon exercise of warrants (in shares)			210,817
Number of shares issuable upon net exercise of outstanding warrants			232,787			4,485
Subsequent Event
Initial Public Offering
Shares of common stock, authorized		100,000,000
Shares of common stock, par value (in dollars per share)		$ 0.0001
Shares of undesignated preferred stock, authorized		10,000,000
Shares of undesignated preferred stock, par value (in dollars per share)		$ 0.0001
Subsequent Event | Common stock warrants
Initial Public Offering
Number of shares issuable upon net exercise of outstanding warrants		463,589
Subsequent Event | Common Stock
Initial Public Offering
Conversion of preferred stock upon public offering (in shares)		5,089,436
Shares issued upon exercise of warrants (in shares)	288,324	202,061
Subsequent Event | IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)		4,300,000
Issuance price (in dollars per share)		$ 12
Net proceeds after deducting underwriting discounts and commissions		$ 55,186
Underwriting discounts and commissions		$ 4,154
Subsequent Event | Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)		645,000
Class A and Class B stock | Subsequent Event
Initial Public Offering
Outstanding common stock (in shares)				5,583,405

Summary of Significant Accoun35

Summary of Significant Accounting Policies - Reverse Stock Split (Details)	Sep. 16, 2016	Sep. 30, 2016shares
Reverse Stock Split
Reverse stock split ratio	0.5155
Number of fractional shares issued		0

Summary of Significant Accoun36

Summary of Significant Accounting Policies - Liquidity (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Summary of Significant Accounting Policies
Substantial doubt about going concern, within one year	false
Cash on hand	$ 1,793	$ 2,026	$ 2,558	$ 4,122

Summary of Significant Accoun37

Summary of Significant Accounting Policies - Deferred Offering Costs (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Offering Costs
Deferred offering costs	$ 3,677	$ 2,298

Summary of Significant Accoun38

Summary of Significant Accounting Policies - Deferred Debt Issuance Costs (Details) - Accounting Standards Update 2015-03 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Other assets
Deferred Debt Issuance Costs
Reclassification from other assets to current portion of long term debt	$ (105)
Current portion of long-term debt.
Deferred Debt Issuance Costs
Reclassification from other assets to current portion of long term debt	$ 105

Net Income (Loss) per Share - E

Net Income (Loss) per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Numerator
Net loss	$ (142)	$ (3,264)	$ (219)	$ (3,949)
Decretion (accretion) of redeemable convertible preferred stock	2,641	(10,802)	2,439	(12,058)
Undistributed income attributable to redeemable convertible preferred stockholders	(1,271)		(1,140)
Net income (loss) attributable to common stockholders, basic	1,228	(14,066)	1,080	(16,007)
Decretion of redeemable convertible preferred stock	(2,641)		(2,439)
Revaluation of warrant liability, net of tax	(661)		(675)
Adjustment to undistributed income attributable to redeemable convertible preferred stockholders	1,271		1,140
Net (loss) attributable to common stockholders, diluted	$ (803)	$ (14,066)	$ (894)	$ (16,007)
Denominator (basic):
Weighted average shares of common stock outstanding, basic	4,918,885	4,379,796	4,817,285	4,232,350
Denominator (diluted):
Weighted average shares of common stock outstanding	4,918,885	4,379,796	4,817,285	4,232,350
Effect of potential dilutive securities:
Dilutive effect from preferred stock and preferred stock warrants assuming conversion	5,414,838		5,414,765
Weighted average shares of common stock outstanding, diluted	10,333,723	4,379,796	10,232,050	4,232,350
Net income (loss) per share attributable to common stockholders, basic (in dollars per share)	$ 0.25	$ (3.21)	$ 0.22	$ (3.78)
Net (loss) per share attributable to common stockholders, diluted (in dollars per share)	$ (0.08)	$ (3.21)	$ (0.09)	$ (3.78)

Net Income (Loss) per Share - A

Net Income (Loss) per Share - Anti-dilutive Securities (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	3,659,645	8,789,244	3,659,645	8,789,244
Stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	2,723,193	2,789,626	2,723,193	2,789,626
Restricted stock
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	722,646		722,646
Common stock warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	213,806	446,593	213,806	446,593
Preferred stock warrants (as converted to common stock)
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share		463,589		463,589
Redeemable convertible preferred stock (as converted to common stock)
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share		5,089,436		5,089,436

Net Income (Loss) per Share - I

Net Income (Loss) per Share - IPO (Details) - Subsequent Event	Oct. 04, 2016$ / sharesshares
IPO
Initial Public Offering
Issuance of common stock upon public offering (in shares)	4,300,000
Issuance price (in dollars per share) | $ / shares	$ 12
Underwriter option
Initial Public Offering
Issuance of common stock upon public offering (in shares)	645,000

Acquisition - Quebec Inc (Detai

Acquisition - Quebec Inc (Details) - Quebec Inc. - USD ($) $ in Thousands	Sep. 15, 2017	Jan. 04, 2017	Dec. 09, 2016	Nov. 18, 2016	Nov. 02, 2016	Sep. 15, 2016	Sep. 30, 2016	Jan. 04, 2017	Sep. 30, 2016	Sep. 15, 2017
Business Acquisition
Cash consideration					$ 2,200	$ 1,000
Threshold number of specified business days for calculating stock consideration to be paid on specified days following the IPO						30 days
Deferred acquisition cash consideration						$ 5,000
Acquisition-date fair value of deferred cash consideration						$ 4,955
Cost of debt (as a percent)						7.80%
Discount						$ 45
Amortization of discount							$ 2		$ 2
Deferred stock consideration						5,000
Acquisition-date fair value of deferred stock consideration						$ 4,445
Discount of stock issuances (as a percent)						10.00%
Plan
Business Acquisition
Cash consideration	$ 600		$ 2,200
Equity consideration		$ 2,500		$ 2,500				$ 5,000
Plan | Maximum
Business Acquisition
Cash consideration										$ 6,000

Acquisition - Purchase Price (D

Acquisition - Purchase Price (Details) - USD ($) $ in Thousands	Sep. 15, 2016	Sep. 30, 2016	Dec. 31, 2015
Allocation of purchase price
Goodwill		$ 21,726	$ 21,606
Developed technology
Allocation of purchase price
Weighted average amortization period		7 years 9 months 4 days	10 years
Trade names
Allocation of purchase price
Weighted average amortization period		5 years	5 years
Quebec Inc.
Allocation of purchase price
Goodwill	$ 120
Total assets acquired	$ 10,400
Weighted average amortization period	6 years 11 months 16 days
Quebec Inc. | Developed technology
Allocation of purchase price
Intangible assets	$ 10,100
Useful life of intangible asset	7 years
Quebec Inc. | Trade names
Allocation of purchase price
Intangible assets	$ 180
Useful life of intangible asset	5 years

Acquisition - Pro forma (Detail

Acquisition - Pro forma (Details) - Quebec Inc. - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition
Revenue	$ 66,788	$ 50,290
Net loss	$ (1,305)	$ (5,064)
Net income (loss) per share attributable to common stockholders, basic	$ 0	$ (2.90)
Net (loss) per share attributable to common stockholders, diluted	$ (0.19)	$ (2.90)

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property and Equipment
Depreciation and amortization expense	$ 1,276	$ 992	$ 3,415	$ 2,935
Property and Equipment
Property and Equipment
Depreciation and amortization expense	$ 359	$ 250	$ 889	$ 729

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Capitalized Computer Software, Net [Abstract]
Gross capitalized software costs	$ 5,875		$ 5,875		$ 4,550
Accumulated amortization	2,802		2,802		2,045
Amortization expense	302	$ 164	757	$ 474
Capitalized software costs not yet subject to amortization	$ 1,136		$ 1,136		$ 888

Goodwill and Intangible Asset47

Goodwill and Intangible Assets - Goodwill (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Goodwill and related changes
Goodwill at beginning of period	$ 21,606
Goodwill from 2016 acquisition	120
Goodwill at end of period	$ 21,726

Goodwill and Intangible Asset48

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Intangible Assets
Gross Value	$ 30,765		$ 30,765		$ 20,456
Accumulated Amortization	(4,536)		(4,536)		(2,769)
Intangible Assets, net	26,229		26,229		$ 17,687
Amortization expense	614	$ 577	$ 1,767	$ 1,730
Trade names
Intangible Assets
Weighted Average Amortization Period (in years)			5 years		5 years
Gross Value	1,900		$ 1,900		$ 1,720
Accumulated Amortization	(696)		(696)		(436)
Intangible Assets, net	1,204		$ 1,204		$ 1,284
Client relationships
Intangible Assets
Weighted Average Amortization Period (in years)			10 years 7 days		10 years 7 days
Gross Value	14,684		$ 14,684		$ 14,684
Accumulated Amortization	(2,919)		(2,919)		(1,810)
Intangible Assets, net	11,765		$ 11,765		$ 12,874
Non-competition agreements
Intangible Assets
Weighted Average Amortization Period (in years)			4 years 7 months 21 days		4 years 7 months 21 days
Gross Value	652		$ 652		$ 652
Accumulated Amortization	(290)		(290)		(183)
Intangible Assets, net	362		$ 362		$ 469
Developed technology
Intangible Assets
Weighted Average Amortization Period (in years)			7 years 9 months 4 days		10 years
Gross Value	13,500		$ 13,500		$ 3,400
Accumulated Amortization	(630)		(630)		(340)
Intangible Assets, net	12,870		$ 12,870		$ 3,060
Domain name
Intangible Assets
Weighted Average Amortization Period (in years)			10 years
Gross Value	29		$ 29
Accumulated Amortization	(1)		(1)
Intangible Assets, net	$ 28		$ 28

Intangible Assets - Amortizatio

Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Estimated amortization expense
2,016	$ 972
2,017	3,782
2,018	3,747
2,019	3,641
2,020	3,301
Thereafter	10,786
Estimated amortization expense	$ 26,229	$ 17,687

Accrued Expenses and Other Li50

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Accrued Liabilities and Other Liabilities
Employee related expenses	$ 2,518	$ 1,232
Deferred revenue	657	520
Interest	358	1,371
Deferred rent	14	94
Other expenses	37	27
Total accrued expenses and other liabilities	$ 3,584	$ 3,244

Notes Payable Related to Acqu51

Notes Payable Related to Acquisition (Details) - Medliance - Subordinated convertible promissory notes - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Dec. 31, 2014	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Notes Payable Related to Acquisition
Aggregate borrowings	$ 16,385
Interest rate (as a percent)	8.00%
Interest expense recognized		$ 330	$ 706	$ 980
Aggregate acquisition date fair values	$ 14,347
Term of debt	18 months
Amortization of discount to interest expense		$ 325	$ 755	$ 906

Lines of Credit and Long-Term52

Lines of Credit and Long-Term Debt - Lines of Credit (Details) - USD ($) $ in Thousands	Jul. 01, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Apr. 29, 2015
Lines of Credit
Amortization of deferred financing costs						$ 1,255	$ 1,575
2015 Revolving Line
Lines of Credit
Maximum borrowing capacity	$ 25,000							$ 15,000
Number of months of monthly recurring revenue through June 30, 2017						4 months
Number of months of monthly recurring revenue thereafter						3 months
Minimum unrestricted cash and unused availability balance required	$ 3,000
Minimum EBITDA			$ 2,250	$ 2,000
Minimum monthly recurring revenue retention rate (as a percent)						90.00%
Aggregate borrowings outstanding			16,000			$ 16,000
Remaining amount available for borrowings			$ 9,000			$ 9,000
Interest rate (as a percent)			4.56%			4.56%
Interest expense			$ 169		$ 109	$ 449	181
Deferred financing costs			141			141
Amortization of deferred financing costs			$ 9		$ 13	$ 36	$ 22
2015 Revolving Line | Plan
Lines of Credit
Minimum EBITDA		$ 2,500
2015 Revolving Line | Prime Rate
Lines of Credit
Spread on variable rate (as a percent)	1.00%
Floor rate (as a percent)	3.50%

Lines of Credit and Long-Term53

Lines of Credit and Long-Term Debt - Term Loan (Details) - USD ($) $ in Thousands	Oct. 04, 2016	Jul. 01, 2016	Dec. 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Jun. 30, 2016
Term loan
Proceeds of initial term loan advance					$ 30,000
Loss on extinguishment of debt				$ (1,396)	(1,396)
Amortization of deferred financing costs					1,255	$ 1,575
Outstanding borrowings				30,000	30,000
Loss on extinguishment of debt				1,396	1,396
ABC Credit Facility
Term loan
Proceeds of initial term loan advance		$ 30,000
Interest rate (as a percent)		12.00%
Interest expense				920	920
Deferred financing costs		$ 1,487
Amortization of deferred financing costs				66	66
Outstanding borrowings				30,000	30,000
Prepayment fee	$ 3,597
ABC Credit Facility | Forecast
Term loan
Loss on extinguishment of debt			$ (5,015)
Loss on extinguishment of debt			$ 5,015
April 2014 Eastward Loan And December 2014 Eastward Loan
Term loan
Original principal balance							$ 15,000
Loss on extinguishment of debt				(1,396)	(1,396)
Loss on extinguishment of debt				$ 1,396	$ 1,396

Lines of Credit and Long-Term54

Lines of Credit and Long-Term Debt - Term Loans and Capital Leases (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Term Loans and Capital Lease Obligations
Present value of payments	$ 30,000
Less discount on debt	(1,421)
Capital leases	1,733	$ 853
Total long-term debt, net	30,312	13,956
Less current portion, net	(29,193)	(13,526)
Total long-term debt, less current portion, net	1,119	430
Tranche A Term Loan
Term Loans and Capital Lease Obligations
Term loans		51
Tranche B Term Loan
Term Loans and Capital Lease Obligations
Term loans		28
April 2014 Eastward Loan
Term Loans and Capital Lease Obligations
Present value of payments		2,260
Unamortized finance costs		(19)
Less discount on debt		(101)
Term loans		2,140
December 2014 Eastward Loan
Term Loans and Capital Lease Obligations
Present value of payments		12,000
Unamortized finance costs		(86)
Less discount on debt		(1,030)
Term loans		$ 10,884
ABC Credit Facility
Term Loans and Capital Lease Obligations
Present value of payments	30,000
Unamortized finance costs	(1,421)
Term loans	$ 28,579

Lines of Credit and Long-Term55

Lines of Credit and Long-Term Debt - Debt Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Term Loans
Remainder of 2016	$ 30,000
Term Loans	30,000
Present value of payments	30,000
Less current portion	(28,579)
Less discount on debt	(1,421)
Capital lease obligations
Remainder of 2016	204
2,017	802
2,018	694
2,019	367
2,020	11
2,021	4
Total	2,082
Less amount representing interest	(349)
Present value of payments	1,733
Less current portion	614
Capital lease obligations	1,119
Total long-term debt
Remainder of 2016	30,204
2,017	802
2,018	694
2,019	367
2,020	11
2,021	4
Total	32,082
Less amount representing interest	(349)
Present value of payments	31,733
Less current portion, net	(29,193)	$ (13,526)
Less discount on debt	(1,421)
Total long-term debt, less current portion, net	$ 1,119	$ 430

Lines of Credit and Long-Term56

Lines of Credit and Long-Term Debt - Other Financing (Details) - AmerisourceBergen Drug Corporation - USD ($) $ in Thousands	1 Months Ended
	May 31, 2016	Sep. 30, 2016	Dec. 31, 2015
Other Financing
Monthly minimum purchase obligation	$ 1,750
Purchase Obligation, Period	3 years
Amount due as a result of prescription drug purchases		$ 3,190	$ 3,691

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Taxes
Tax expense	$ (164)	$ 36	$ 11	$ 212
Effective tax rate			(5.30%)	(5.70%)

Other Long-term Liabilities (De

Other Long-term Liabilities (Details) $ in Thousands	Sep. 30, 2016USD ($)
Other Long-term Liabilities.
Other Long-term Liabilities
Long-term portion of deferred rent	$ 1,973

Stockholders' Deficit and Red59

Stockholders' Deficit and Redeemable Convertible Preferred Stock - Common Stock (Details) - Common Stock $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)Vote
Common Stock
Dividend declared (in dollars) | $	$ 0
Class B common stock
Common Stock
Number of votes per share | Vote	1

Stockholders' Deficit and Red60

Stockholders' Deficit and Redeemable Convertible Preferred Stock - Convertible Preferred Stock (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Series A redeemable convertible preferred stock
Redeemable Convertible Preferred Stock
Aggregate amount of cumulative unpaid dividends	$ 1,223
Series A-1 redeemable convertible preferred stock
Redeemable Convertible Preferred Stock
Aggregate amount of cumulative unpaid dividends	661
Series B redeemable convertible preferred stock
Redeemable Convertible Preferred Stock
Aggregate amount of cumulative unpaid dividends	$ 944

Stockholders' Deficit and Red61

Stockholders' Deficit and Redeemable Convertible Preferred Stock - Common Stock Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Warrants
Interest expense	$ 1,242	$ 1,468	$ 4,250	$ 4,418
Common stock warrants
Warrants
Exercise Price (in dollars per share)		$ 6.40		$ 6.40
Number of shares called by warrants issued	232,787	4,485	232,787	4,485
Interest expense			$ 0	$ 16
Warrants issued (in shares)			0
Shares issued upon exercise of warrants (in shares)			210,817
Common stock warrant one | Class A common stock
Warrants
Number of Warrants	106,361		106,361
Exercise Price (in dollars per share)	$ 0.480		$ 0.480
Term (in years)			10 years
Common stock warrant two | Class B common stock
Warrants
Number of Warrants	82,471		82,471
Exercise Price (in dollars per share)	$ 0.480		$ 0.480
Term (in years)			10 years
Common stock warrant three | Class A common stock
Warrants
Number of Warrants	7,731		7,731
Exercise Price (in dollars per share)	$ 0.530		$ 0.530
Term (in years)			10 years
Common stock warrant four | Class A common stock
Warrants
Number of Warrants	5,154		5,154
Exercise Price (in dollars per share)	$ 0.970		$ 0.970
Term (in years)			10 years
Common stock warrant five | Class A common stock
Warrants
Number of Warrants	515		515
Exercise Price (in dollars per share)	$ 0.970		$ 0.970
Term (in years)			10 years
Common stock warrant six | Class B common stock
Warrants
Number of Warrants	2,577		2,577
Exercise Price (in dollars per share)	$ 0.480		$ 0.480
Term (in years)			10 years
Common stock warrant seven | Class B common stock
Warrants
Number of Warrants	4,982		4,982
Exercise Price (in dollars per share)	$ 3.100		$ 3.100
Term (in years)			10 years
Common stock warrant eight | Class B common stock
Warrants
Number of Warrants	4,015		4,015
Exercise Price (in dollars per share)	$ 5.820		$ 5.820
Term (in years)			10 years

Stockholders' Deficit and Red62

Stockholders' Deficit and Redeemable Convertible Preferred Stock - Common Stock Warrants Valuation (Details) - Common stock warrants	9 Months Ended
	Sep. 30, 2015
Valuation assumptions:
Expected volatility	50.00%
Expected life (years)	10 years
Risk-free interest rate	2.13%

Stockholders' Deficit and Red63

Stockholders' Deficit and Redeemable Convertible Preferred Stock - Preferred Stock Warrants (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Oct. 04, 2016
Preferred stock warrants
Warrants
Warrants issued (in shares)	0	0
Preferred Stock Warrant One | Series A-1 redeemable convertible preferred stock
Warrants
Number of Warrants	250,000
Exercise Price (in dollars per share)	$ 0.800
Term (in years)	10 years
Preferred Stock Warrant Two | Series A-1 redeemable convertible preferred stock
Warrants
Number of Warrants	62,500
Exercise Price (in dollars per share)	$ 0.800
Term (in years)	10 years
Preferred Stock Warrant Three | Series B redeemable convertible preferred stock
Warrants
Number of Warrants	105,005
Exercise Price (in dollars per share)	$ 2.860
Term (in years)	10 years
Preferred Stock Warrant Four | Series B redeemable convertible preferred stock
Warrants
Number of Warrants	481,863
Exercise Price (in dollars per share)	$ 2.990
Term (in years)	10 years
Common stock warrants
Warrants
Exercise Price (in dollars per share)		$ 6.40
Warrants issued (in shares)	0
Number of shares called by warrants issued	232,787	4,485
Common stock warrants | Subsequent Event
Warrants
Number of shares called by warrants issued			463,589

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2016	Sep. 28, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Aug. 31, 2016
Stock-Based Compensation
Stock-based compensation expense (in dollars)			$ 223	$ 159	$ 481	$ 471
2014 Plan
Stock-Based Compensation
Authorized shares of common stock	4,037,981		4,037,981		4,037,981		3,935,865
2014 Plan | Restricted stock
Stock-Based Compensation
Grants (in shares)	0	700,386
Initial public offering price (in dollars per share)		$ 12
Stock-based compensation expense (in dollars)			$ 102		$ 102
Unrecognized compensation expense (in dollars)	$ 8,302		$ 8,302		$ 8,302
2014 Plan | Class A common stock
Stock-Based Compensation
Authorized shares of common stock	2,702,443		2,702,443		2,702,443
2014 Plan | Class B common stock
Stock-Based Compensation
Authorized shares of common stock	1,335,538		1,335,538		1,335,538
2016 Plan
Stock-Based Compensation
Threshold limit to issue or transfer authorized shares (in shares)	800,000		800,000		800,000
Automatic increase on share reserve (as a percent)					5.00%
Available for future grant (in shares)	777,740		777,740		777,740
2016 Plan | Restricted stock
Stock-Based Compensation
Grants (in shares)		22,260
Initial public offering price (in dollars per share)		$ 12
Stock-based compensation expense (in dollars)			$ 1		$ 1
Unrecognized compensation expense (in dollars)	$ 266		$ 266		$ 266
2016 Plan | Restricted Stock, Initial grant
Stock-Based Compensation
Annual vesting (as a percent)		33.33%
Vesting period		3 years
2016 Plan | Restricted Stock, Annual grant | Maximum
Stock-Based Compensation
Vesting period		1 year
Leadership Exit Bonus Plan and Equity Compensation Plan 2016
Stock-Based Compensation
Initial public offering price (in dollars per share)	$ 12		$ 12		$ 12
Leadership Exit Bonus Plan and Equity Compensation Plan 2016 | Restricted stock
Stock-Based Compensation
Awards approved, but not yet granted (in shares)	13,362		13,362		13,362
Stock to be withheld for tax withholdings (in shares)			7,010
Issuance of restricted stock (in shares)					0

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 223	$ 159	$ 481	$ 471
Stock options
Stock-Based Compensation
Stock-based compensation expense (in dollars)	$ 120	$ 159	$ 378	$ 471
Stock options
Valuation assumptions:
Expected volatility (as a percent)			59.00%	55.12%
Expected life			6 years 29 days	6 years 18 days
Risk-free interest rate (as a percent)			1.49%	1.75%

Stock-Based Compensation - Op66

Stock-Based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
2016 Plan
Number of shares
Outstanding at beginning of the period (in shares)	2,791,754
Granted (in shares)	6,310
Exercised (in shares)	(71,150)
Forfeited (in shares)	(3,721)
Outstanding at end of the period (in shares)	2,723,193		2,791,754
Options vested and expected to vest at end of the period (in shares)	2,723,193
Exercisable at end of the period (in shares)	2,239,139
Weighted average exercise price
Outstanding at beginning of the period (in dollars per share)	$ 3.27
Granted (in dollars per share)	13.17
Exercised (in dollars per share)	1.45
Forfeited (in dollars per share)	7.36
Outstanding at end of the period (in dollars per share)	3.33		$ 3.27
Options vested and expected to vest at end of the period (in dollars per share)	3.33
Exercisable at end of the period (in dollars per share)	$ 2.92
Weighted average remaining contractual term
Outstanding	6 years 3 months 18 days		7 years
Options vested and expected to vest at end of the period	6 years 3 months 18 days
Exercisable	6 years
Aggregate intrinsic value
Outstanding (in dollars)	$ 29,991		$ 27,239
Options vested and expected to vest at end of the period (in dollars)	29,991
Exercisable (in dollars)	25,529
Stock options | 2016 Plan
Unrecognized compensation cost and recognition period disclosure
Total unrecognized compensation cost	$ 906
Weighted average period expected to be recognized	1 year 6 months
Stock options
Aggregate intrinsic value
Weighted average grant-date fair value (in dollars per share)	$ 7.29	$ 3.23
Non-employee options | 2016 Plan
Number of shares
Outstanding at end of the period (in shares)	217,747
Aggregate intrinsic value
Unvested options (in shares)	2,446

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 223	$ 159	$ 481	$ 471
Cost of revenue - product
Stock-based compensation expense
Stock-based compensation expense (in dollars)	27	25	85	75
Cost of revenue - service
Stock-based compensation expense
Stock-based compensation expense (in dollars)	7	7	21	17
Research and development
Stock-based compensation expense
Stock-based compensation expense (in dollars)	9	6	30	14
Selling and marketing
Stock-based compensation expense
Stock-based compensation expense (in dollars)	21	21	65	68
General and administrative
Stock-based compensation expense
Stock-based compensation expense (in dollars)	$ 159	$ 100	$ 280	$ 297

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities (Details) - Recurring - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value Measurements
Note payable related to acquisition		$ 15,620
Acquisition-related contingent consideration - short-term	$ 1,634	1,886
Acquisition-related contingent consideration - long-term	1,858	3,355
Liabilities	8,422	26,430
Level 3
Fair Value Measurements
Note payable related to acquisition		15,620	$ 14,347
Acquisition-related contingent consideration - short-term	1,634	1,886
Acquisition-related contingent consideration - long-term	1,858	3,355
Liabilities	8,422	26,430
Warrant liability
Fair Value Measurements
Warrant liability	4,930	5,569
Warrant liability | Level 3
Fair Value Measurements
Warrant liability	$ 4,930	$ 5,569

Fair Value Measurements - Prefe

Fair Value Measurements - Preferred Stock Warrants Valuation (Details) - Preferred stock warrants - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Weighted-average assumptions:
Estimated life	7 years 2 months 27 days	7 years 11 months 27 days
Dividend yield	0.00%	0.00%
Risk-free interest rate	1.40%	2.10%
Fair value of underlying instrument	$ 14.32	$ 8.14
Volatility	59.69%	57.81%
Discount for lack of marketability	10.00%	10.00%

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liability (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Warrant liability
Change in fair value using significant unobservable inputs (Level 3):
Balance at beginning of period	$ 5,569
Change in / Adjustments to fair value	(639)
Balance at end of period	4,930
Acquisition related contingent consideration
Change in fair value using significant unobservable inputs (Level 3):
Balance at beginning of period	5,241
Fair value of cash consideration paid	(1,895)
Change in / Adjustments to fair value	146
Balance at end of period	$ 3,492

Related-Party Transactions (Det

Related-Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Related-Party Transactions
Notes payable to related parties	$ 250		$ 250		$ 250
Interest rate (as a percent)	6.00%		6.00%		6.00%
Total interest expenses	$ 4	$ 10	$ 11	$ 38

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 12, 2016	Oct. 04, 2016	Oct. 31, 2016	Sep. 30, 2016	Sep. 30, 2015
Common stock warrants
Subsequent Event
Shares issued upon exercise of warrants (in shares)				210,817
Number of shares issuable upon net exercise of outstanding warrants				232,787	4,485
Leadership Exit Bonus Plan and Equity Compensation Plan 2016
Subsequent Event
Issuance price (in dollars per share)				$ 12
Subsequent Event | Common Stock
Subsequent Event
Shares issued upon exercise of warrants (in shares)	288,324	202,061
Subsequent Event | Common stock warrants
Subsequent Event
Number of shares issuable upon net exercise of outstanding warrants		463,589
Number of warrants exercised (in shares)	431,373
Subsequent Event | Leadership Exit Bonus Plan and Equity Compensation Plan 2016
Subsequent Event
Issuance price (in dollars per share)			$ 12
Shares issued net of shares for tax withholding (in shares)			13,362
Shares paid for tax withholding (in shares)			7,010
Value of shares issued net of shares for tax withholding			$ 244
IPO | Subsequent Event
Subsequent Event
Issuance of common stock upon public offering (in shares)		4,300,000
Issuance price (in dollars per share)		$ 12
Underwriter option | Subsequent Event
Subsequent Event
Issuance of common stock upon public offering (in shares)		645,000